Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
Combination therapy in patients with relapsing-remitting multiple sclerosis (MS) CombiRx
[Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine].
Rituximab (marketed as Rituxan), Information
Posturography in MS patients treated with high dose methylprednisolone.
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Klotho Is a Neuroprotective and Cognition-Enhancing Protein.
Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers.
Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease.
Interferon-beta is a potent promoter of nerve growth factor production by astrocytes.
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
Interleukin-10 but not transforming growth factor-β1 gene expression is up-regulated by vitamin D treatment in multiple sclerosis patients.
Neuroimmunology: Clostridium-reactive T cells are implicated in the pathogenesis of neuromyelitis optica.
Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9.
Spectrum of nontraumatic myelopathies in Ethiopian patients: hospital-based retrospective study.
Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.
Autoimmunity in visual loss.
IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial.
Gpr126 functions in Schwann cells to control differentiation and myelination via G-protein activation.
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.
Nanoparticle transport across the blood brain barrier.
Regulation of B cell function by the immunosuppressive agent leflunomide.
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.

Pages